Blackstone bets $1.5B on Pfizer’s obesity drug
The deal will support a sprawling Phase 3 program for a monthly GLP-1 shot Pfizer acquired by winning a bidding war for the drug’s previous owner, Metsera.
Blackstone has supported Pfizer's initiative to launch a monthly treatment for obesity, as reported in STAT+. The biotech news outlet highlights several key developments in the pharmaceutical industry. Bristol Myers Squibb has restructured its R&D organization, with Chief Medical Officer Cristian Massacesi now also serving as head of R&D.
Robert Plenge, who headed research, will leave the company in March. The FDA has suspended the Commissioner's National Priority Voucher program, according to Reuters. The nomination of Heidi Overton to lead the FDA is facing a crucial Senate vote on Wednesday, with Republicans divided over her potential nomination. Committee Chair Bill Cassidy has expressed reservations about Overton's suitability, citing her role in the Trump administration's vaccine policies as a potential disqualifier.
The outcome of this vote could be significantly impacted by a single Republican defection, as Democrats are poised to oppose her nomination.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
